12th CTSS Conference- Live at BOSTON

The 12th CTSS conference opened doors to a world of possibilities as we engaged with passionate clinical research enthusiasts from across the globe and shared insights into latest trends and demands of the clinical industry.

Our CEO, Dr. Gill, took center stage at our booth, captivating visitors and partners with a dazzling presentation that unveiled OrciTrials’ trailblazing services and solutions towards the Clinical industry and strong networking environment.

The event’s resounding success and the tremendous response have left us exhilarated. At OrciTrials, we firmly believe that true triumph stems from forging robust partnerships and fostering collaborative networks. Join us on this exciting journey as we shape the future of the clinical industry together.




Eid Lunch

Team OrciTrials recently gathered for an EID lunch filled with joy and laughter! It was a wonderful celebration of this special occasion, as the Team shared heartwarming Eid stories and exchanged thoughtful gifts outside of work.

At OrciTrials, we prioritize team building and creating a positive work culture. Our recent EID lunch provided a chance for our team to come together, celebrate, and bond over shared experiences. We believe that encouraging recreational activities and events outside of work fosters a sense of community and belonging, which ultimately leads to a more productive and collaborative work environment. 

We are proud of our team’s dedication to their work and willingness to participate in these activities and We hope to continue this tradition of celebrating together and fostering a positive and inclusive work environment.



Team Iftar Dinner

As Ramadan continues, Muslims worldwide observe the month-long fast, and Iftar becomes a special occasion to gather with family, loved ones, friends, and colleagues to reflect, express gratitude, and strengthen bonds. At OrciTrials, we believe that our team is more than just a group of colleagues – we are a family. That’s why our CEO, Jawad Gill, hosted a heart-warming Iftar dinner for the entire team at Lahore spreading the spirit of Ramadan.

The evening was filled with joy, laughter, and a sense of togetherness. As team gathered around the table, shared stories and strengthened bonds as a team.

OrciTrials has always valued every member of its family, and events like this allow  to connect on a personal level and remind of the importance of supporting each other.

OrciTrials look forward to more opportunities to strengthen its bonds and build a strong team.

Untitled design (26)

Exploring the Landscape of Clinical Trials in Pakistan: Opportunities and Progress

Clinical trials play a role in the development of medications and therapies that can have a positive impact on global health outcomes. However, it is crucial to prioritize diversity and inclusivity in these trials to ensure that everyone regardless of their ethnicity, location or socioeconomic status can benefit from advancements. We will explore the significance of diversity in trials and the emerging opportunities in Pakistan a country burdened with health challenges. Additionally, we will delve into the role of OrciTrials—a Contract Research Organization (CRO)—in supporting clinical trial monitoring and ensuring quality assurance services in Pakistan.

It is important for clinical trials to accurately represent the population to guarantee that new treatments and therapies are safe and effective for everyone. Unfortunately, there has been underrepresentation of demographics—especially minorities and individuals from developing countries—which raises concerns. This lack of representation can lead to results. Restrict the applicability of treatments when it comes to diverse patient populations.

The Significance of Diversity in Clinical Trials. 

Ensuring Safety and Efficacy; Including a range of participants in trials helps identify potential variations in how treatments affect different populations ultimately ensuring safety and efficacy for all. Diverse clinical trial participants ensure that the findings are applicable to a broader segment of the population. This inclusivity is critical because different ethnicities, ages, genders, and genetic backgrounds can respond differently to treatments and therapies. Diversity in clinical trials is not just a matter of ethical consideration but a fundamental requirement for advancing healthcare and ensuring that medical research benefits all members of society equitably. By including a diverse range of participants, researchers can develop safer, more effective treatments and therapies that address the unique needs of various populations. 

Clinical Trials in Pakistan.

Pakistan offers a special potential for conducting clinical trials because of its diversified population and heavy disease load. In Pakistan, several important disease areas have significant prevalence rates. 

  1. Diabetes: The highest diabetes prevalence rates in the world is in Pakistan. It is crucial to conduct trials for the management and treatment of diabetes. According to the International Diabetes Federation (IDF), the prevalence of diabetes in Pakistan is 26.7%, which means that about 33 million adults in Pakistan have diabetes. The IDF ranked Pakistan first place for having the highest comparative diabetes prevalence rate in 2021 at 30.8 percent.   
  2. Breast Cancer: Breast cancer is the most prevalent cancer in Pakistan, making it necessary to do research into novel treatments, early detection techniques, and prevention measures. According to the Pakistan Cancer Society, breast cancer accounts for about 30% of all cancers in women. The incidence of breast cancer in Pakistan is increasing. In 2018, there were an estimated 60,000 new cases of breast cancer in Pakistan. This number is expected to increase to 100,000 new cases by 2030.
  3. Infectious Diseases: Malaria and tuberculosis (TB) are two of the most prevalent infectious diseases in Pakistan. Controlling these diseases depends on clinical trials for new medications and vaccinations. Malaria is the leading cause of death among children under 5 years of age in Pakistan. According to the World Health Organization (WHO), an estimated 2.5 million people in Pakistan are infected with malaria each year. TB is the second leading cause of death among adults in Pakistan. According to WHO, an estimated 570,000 people in Pakistan are infected with TB each year.

Supporting Clinical Trials in Pakistan with OrciTrials

  1. Clinical Trial Planning: To plan and design clinical trials that address Pakistan’s particular healthcare concerns, OrciTrials works with Biotech and pharmaceutical companies.
  2. Patient Recruitment: To ensure that clinical trial data appropriately reflects Pakistan’s population, OrciTrials makes use of its broad network to draw in a wide group of participants.
  3. Clinical Monitoring: OrciTrials offers extensive monitoring services, ensuring the integrity and dependability of trial data through meticulous oversight and adherence to strict criteria.
  4. Clinical Quality Assurance: OrciTrials provides comprehensive quality assurance services to guarantee the reliability of trial data, maintaining the highest standards and adherence to strict criteria.
  5. Ethical Issues: OrciTrials complies with stringent ethical standards, guaranteeing that clinical trials in Pakistan are carried out with the highest respect for participants’ rights and well-being.

Medical progress depends heavily on clinical trials, and the inclusion of diverse participants is essential to the studies’ success and the provision of fair healthcare. Pakistan presents a wealth of chances for conducting clinical trials, notably in fields like diabetes, breast cancer, and infectious diseases, due to its significant disease load. The integrity and quality of these studies are crucially maintained by contract research organizations like OrciTrials, which helps to advance healthcare in Pakistan and around the world. We get closer to achieving global health parity by embracing diversity and conducting trials in underdeveloped nations like Pakistan.


Meeting with a potential client

OrciTrials CEO, Dr. Jawad Gill welcomed and hosted potential clients — a promising Biotech company —over lunch in Lahore.
After a very fruitful meeting , we move forward to continued collaboration between both companies.

OrciTrials believes in creating stronger ties within the clinical research industry and working beyond borders.

OrciTrials look forward to further strengthening their relationships with all clinical research stakeholders in Pakistan and fostering a collaborative culture in the industry.


Team Lunch

After more than 6 months of virtual work, OrciTrials core leadership team finally reunited for lunch in beautiful Lahore! Two of company directors, Kafait and Hassan also visited from the UK to join Pakistan Team  and help drive business goals in the region.

OrciTrials look forward to further strengthening their relationships with all clinical research stakeholders in Pakistan and fostering a collaborative culture in the industry.

orci celeb

Lahore Office Inauguration

OrciTrials officially inaugurated its Lahore office in March 2022 with a small gathering of employees and key stakeholders. The occasion was embellished by a delicious homemade cake displaying the company logo, along with balloons and flowers which made the workspace come alive.

OrciTrials celebrated this small but an important milestone on the way to establishing a local presence and becoming a leading CRO in Pakistan.